Halozyme to Showcase Innovations at 8th Annual Evercore Healthcare Conference

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that Dr. Helen Torley, the company’s President and CEO, will represent Halozyme at the upcoming 8th Annual Evercore Healthcare Conference. This notable event is scheduled to take place on December 2, where Dr. Torley will host investor meetings and deliver a presentation aimed at showcasing Halozyme's latest advancements in biopharmaceutical technology.

The presentation is set for 10:20 AM PT / 1:20 PM ET and will be accessible through a live audio webcast available in the Investor Relations section of Halozyme's website. For those interested in revisiting the insights shared during the presentation, the audio webcasts will be available for replay for 90 days after the conference.

About Halozyme

Halozyme is dedicated to pioneering transformative solutions that enhance the patient experience and improve therapeutic outcomes for both emerging and established treatments. The company is recognized for its innovative ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to enable the subcutaneous administration of injected therapies. This method significantly reduces the burden of treatment for patients, offering greater convenience and improving their overall healthcare experience. Notably, ENHANZE® has positively impacted the lives of over one million patients worldwide through ten commercialized products available in more than 100 global markets.

The technology has attracted the attention of leading pharmaceutical and biotechnology partners, including industry giants like Roche, Takeda, and Pfizer. This strong network is a testament to the effectiveness and reliability of Halozyme's solutions in drug delivery.

In addition to ENHANZE®, Halozyme is advancing its portfolio with Hypercon™, a cutting-edge microparticle technology specifically designed to expand the applications of drug delivery by enabling hyper-concentration of therapeutic drugs and biologics. This innovation is structured to reduce injection volumes for patients without compromising dosage, thus broadening the potential for at-home and healthcare provider administration of therapies. By incorporating Hypercon™, Halozyme aims to transform treatment experiences significantly, facilitating the accessibility and administration of more concentrated biologics.

Furthermore, Halozyme is involved in the development and commercialization of various drug-device combination products utilizing modern auto-injector technologies. These products enhance patient comfort and adherence, making treatments more manageable. The company’s proprietary products, Hylenex® and XYOSTED®, alongside partnered commercial offerings, exemplify its commitment to improving patient care through reliable and user-friendly medical solutions.

Halozyme’s operations are headquartered in San Diego, California, with additional offices located in Ewing, New Jersey, Minnetonka, Minnesota, and Boston, Massachusetts. The Minnetonka location serves as an operational facility, supporting the company's infrastructure and research initiatives.

For more information about Halozyme and its comprehensive range of products and innovations, interested parties can visit www.halozyme.com and engage with the company on LinkedIn and Twitter for the latest updates and insights.

Contact Information

For media inquiries or further information, please contact:
Tram Bui
VP, Investor Relations and Corporate Communications
Phone: 609-333-7668
Email: [email protected]

Halozyme’s forward-looking strategies and innovations aim to not only enhance drug delivery systems but to also improve the quality of life for patients around the globe, an initiative that will be further detailed during the Evercore Healthcare Conference.